Description
Axitinib is an inhibitor of VEGFR that exhibits anticancer chemotherapeutic and anti-angiogenic activities. Axitinib is currently in clinical trials as a potential treatment for renal cell carcinoma. In vitro, axitinib increases levels of CD8+ T cells and decreases levels of myeloid-derived suppressor cells, inhibiting proliferation and increasing apoptosis. In vivo, this compound inhibits expression of iNOS, arginase, IL-6, TNF-α, and IFN-γ, increasing apoptosis and inhibiting tumor growth. In animal models of lung adenocarcinoma, axitinib decreases tumor vasculature and lesion growth.
References
Zhang X, Fang X, Gao Z, et al. Axitinib, a selective inhibitor of vascular endothelial growth factor receptor, exerts an anticancer effect in melanoma through promoting antitumor immunity. Anticancer Drugs. 2014 Feb;25(2):204-11. PMID: 24135499.
Gross-Goupil M, François L, Quivy A, et al. Axitinib: A Review of its Safety and Efficacy in the Treatment of Adults with Advanced Renal Cell Carcinoma. Clin Med Insights Oncol. 2013 Oct 29;7:269-277. PMID: 24250243.
Majeti BK, Lee JH, Simmons BH, et al. VEGF is an important mediator of tumor angiogenesis in malignant lesions in a genetically engineered mouse model of lung adenocarcinoma. BMC Cancer. 2013 Apr 29;13(1):213. [Epub ahead of print]. PMID: 23627488.
